Insulet Announces Omnipod® 5 Automated Insulin Delivery System is Now Available in the United Kingdom
20 Junho 2023 - 5:01PM
Business Wire
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the
global leader in tubeless insulin pump technology with its Omnipod®
brand of products, today announced the commercial launch of its
Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for
individuals aged two years and older with type 1 diabetes (T1D) in
the United Kingdom (UK).
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230620673527/en/
Omnipod® 5 Automated Insulin Delivery
System (Photo: Business Wire)
“Since its commercial launch in the United States, Omnipod 5 has
had a remarkable impact on people with diabetes,” said Jim
Hollingshead, Insulet President and CEO. “Every day, we hear how
this revolutionary experience of Omnipod 5 reduces the burden and
improves quality of life for people with diabetes, and we are
excited to make a difference in other parts of the world, beginning
with the UK. We are committed to making Omnipod 5 an option for as
many people as possible, as quickly as we can, and working hard to
secure broad access globally.”
The Omnipod 5 System is where simplicity meets advanced
technology. Omnipod 5 is the first CE marked tubeless hybrid closed
loop system (also known as automated insulin delivery) that
integrates with the Dexcom G6 Continuous Glucose Monitoring (CGM)
System to automatically adjust insulin delivery and help protect
against high and low glucose levels1. The system2 consists of the
tubeless Pod enhanced with SmartAdjust™ technology and the Omnipod
5 Controller with its integrated SmartBolus Calculator. The system
is interoperable with the Dexcom G6 CGM for automated insulin
delivery.
Every five minutes, SmartAdjust technology receives a CGM value
and trend, and predicts where glucose will be 60 minutes into the
future. The system then increases, decreases, or pauses insulin
delivery based on the user’s desired and customized glucose target.
Omnipod 5 simplifies daily diabetes management by making many of
these dosing decisions for the user, while they focus on other
aspects of their life.
Lydia Parkhurst, a 26-year-old geography teacher who enjoys
backpacking and has travelled the world with her Omnipod DASH®
System, has been a Podder since 2015. “I am so excited for the
release of Omnipod 5 in the UK,” said Lydia. “I can’t wait to
experience the freedom of being tubeless while also having the
support of hybrid closed loop technology. The combination will make
living with type 1 diabetes far less complicated – allowing me to
live my life to the fullest!”
“With NICE3 set to approve hybrid closed loop in England and
Wales later this year, we are delighted that more hybrid closed
loop systems such as Omnipod 5 are becoming available to help
people manage their type 1 diabetes,” said Karen Addington, CEO at
JDRF UK. “Diabetes management is very personal, so access to a
range of technology options is crucial. A wider choice of hybrid
closed loop systems offers people with type 1 diabetes
evidence-based treatment they can trust to support them to manage
their condition with confidence.”
Insulet is working in partnership with the National Health
Service (NHS) at all levels to ensure access to Omnipod 5 for
people with type 1 diabetes.
Insulet plans to release Omnipod 5 in Germany in the fall of
2023.
To learn more about Omnipod 5, visit the Omnipod website.
1Study in 240 people with T1D aged 6 to 70 years involving two
weeks standard diabetes therapy followed by three months Omnipod 5
use in Automated Mode. Average time with high blood glucose in
adults/adolescents and children, standard therapy vs. three-month
Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%. Median time with low
blood glucose in adults/adolescents and children, standard therapy
vs. three-month Omnipod 5: 2.0% vs. 1.1%; 1.4% vs. 1.5%. Brown et.
al. Diabetes Care (2021). Study in 80 children with T1D aged 2 to
5.9 years involving two weeks of standard diabetes therapy followed
by three months Omnipod 5 use in Automated Mode. Average overnight
time (12AM-6AM) with high blood glucose in children for standard
therapy vs. Omnipod 5 was 38.4% vs. 16.9%. Average day time
(6AM-12AM) with high blood glucose in children for standard therapy
vs. Omnipod 5 was 39.4% vs. 29.5%. Median overnight time (12AM-6AM)
with low blood glucose in children for standard therapy vs. Omnipod
5 was 3.41% vs. 2.13%. Median day time (6AM-12AM) with low blood
glucose in children for standard therapy vs. Omnipod 5 was 3.43%
vs. 2.46%. Sherr J, et. al. Diabetes Care (2022).
2Integration with the Dexcom G6 CGM is required for automated
insulin delivery.
3National Institute of Health and Care Excellence.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in
Massachusetts, is an innovative medical device company dedicated to
simplifying life for people with diabetes and other conditions
through its Omnipod product platform. The Omnipod Insulin
Management System provides a unique alternative to traditional
insulin delivery methods. With its simple, wearable design, the
tubeless disposable Pod provides up to three days of non-stop
insulin delivery, without the need to see or handle a needle.
Insulet’s flagship innovation, the Omnipod 5 Automated Insulin
Delivery System, integrates with a continuous glucose monitor to
manage blood sugar with no multiple daily injections, zero
fingersticks, and can be controlled by a compatible smartphone or
Omnipod 5 Controller. Insulet also leverages the unique design of
its Pod by tailoring its Omnipod technology platform for the
delivery of non-insulin subcutaneous drugs across other therapeutic
areas. For more information, please visit: insulet.com and
omnipod.com.
Forward-Looking Statement:
This press release may contain forward-looking statements
concerning Insulet's expectations, anticipations, intentions,
beliefs, or strategies regarding the future. These forward-looking
statements are based on its current expectations and beliefs
concerning future developments and their potential effects on
Insulet. There can be no assurance that future developments
affecting Insulet will be those that it has anticipated. These
forward-looking statements involve a number of risks, uncertainties
(some of which are beyond its control) or other assumptions that
may cause actual results or performance to be materially different
from those expressed or implied by these forward-looking
statements, and other risks and uncertainties described in its
Annual Report on Form 10-K, which was filed with the Securities and
Exchange Commission on February 24, 2023 in the section entitled
"Risk Factors," and in its other filings from time to time with the
Securities and Exchange Commission. Should one or more of these
risks or uncertainties materialize, or should any of its
assumptions prove incorrect, actual results may vary in material
respects from those projected in these forward-looking statements.
Insulet undertakes no obligation to publicly update or revise any
forward-looking statements.
©2023 Insulet Corporation. Omnipod, Omnipod DASH, Omnipod 5, and
SmartAdjust are trademarks or registered trademarks of Insulet
Corporation in the United States of America and various other
jurisdictions. All rights reserved. All other trademarks are the
property of their respective owners. The use of third-party
trademarks does not constitute an endorsement or imply a
relationship or other affiliation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230620673527/en/
Investor Relations: Deborah R. Gordon Vice President,
Investor Relations (978) 600-7717 dgordon@insulet.com
Media: Angela Geryak Wiczek Senior Director, Corporate
Communications (978) 932-0611 awiczek@insulet.com
Insulet (NASDAQ:PODD)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Insulet (NASDAQ:PODD)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024